The German pharmaceutical company BioNTech and its U.S. partner Pfizer have launched a new study on the effectiveness and safety of a new vaccine candidate.
The new vaccine would work according to the same mRNA technology as the existing Corona vaccines developed by BioNTech and Pfizer, the two pharmaceutical companies say.
The vaccine candidate is now in the second phase of clinical trials, involving approximately 200 subjects in the United States.
For this “next-generation vaccine candidate,” the spike protein is being modified with the aim of increasing the magnitude of the immune response to improve protection against COVID-19.
“This is the first in a series of vaccine candidates with a modified design,” the pharmaceutical companies said. Both spoke of a long-term, science-based vaccine strategy to elicit “potentially more robust, longer-lasting and broader immune responses” to Corona infections.
